View:
Mini BasicThis view is available after user registration.
ShortThis view is available when you buy a license.
StandardThis view is available when you buy a license.
CompleteThis view is available when you buy a license.
Pembrolizumab 200 / Trastuzumab 6 / Oxaliplatin 130 / Capecitabine 1000, Adenocarcinoma Esophagogastric Junction and Stomach, Cycle 2+
Protocol-ID: 2094 V1.2 (Mini), PEMB200/TRAS6/OXAL130/CAPE1000, AEG/Gastric Ca, C2+Indication(s)
- Gastric Cancer (HER2+); ICD-10 C16.-, C16.0
- Esophageal Cancer (Adenocarcinoma Esophagogastric Junction (AEG), HER2+); ICD-10 C15.-
Links
- Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC). [ASCO Abstracts doi]
 | The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti. |
Valid since: 22.02.2024